Information Provided By: 
Fly News Breaks for May 20, 2019
MDCO, ALNY
May 20, 2019 | 07:08 EDT
Alnylam Pharmaceuticals' (ALNY) partner, the Medicines Company (MDCO), presented on Saturday data from the ORION-3 trial of inclisiran, Nomura Instinet analyst Christopher Marai tells investors in a research note. The update did not suggest any surprise safety signals, as expected, but only limited safety data, according to Marai. He believes inclisiran's opportunity is a "show-me story" and more likely to become priced in post-approval after material sales. The analyst reiterates a Reduce rating on Alnylam shares with a $62 price target.
News For ALNY;MDCO From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
